News Releases

Date Title  
Toggle Summary US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
SAN DIEGO , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses.  Ulcers are common in the majority of horses that are subject to stress. 
US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
SAN DIEGO , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses.  Ulcers are common in the majority of horses that are subject to stress. 
Toggle Summary Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose
SAN DIEGO , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to begin testing the drug compound naloxone in human patients. 
Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose
SAN DIEGO , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to begin testing the drug compound naloxone in human patients. 
Toggle Summary Adamis Pharmaceuticals Announces Presentation of a Human Factors Study Results for Symjepi at the AAAAI Joint Congress With the World Allergy Organization
SAN DIEGO, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( ADMP ) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic Reactions (Type I)
Adamis Pharmaceuticals Announces Presentation of a Human Factors Study Results for Symjepi at the AAAAI Joint Congress With the World Allergy Organization
SAN DIEGO, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( ADMP ) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic Reactions (Type I)
Toggle Summary Adamis Pharmaceuticals Submits Prior Approval Supplement to FDA for the Pediatric Version of Symjepi
SAN DIEGO , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the submission of a prior approval supplement to the U.S. Food and Drug Administration (“FDA”) for a pediatric version (0.15mg) of Symjepi™.
Adamis Pharmaceuticals Submits Prior Approval Supplement to FDA for the Pediatric Version of Symjepi
SAN DIEGO , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the submission of a prior approval supplement to the U.S. Food and Drug Administration (“FDA”) for a pediatric version (0.15mg) of Symjepi™.
Toggle Summary Adamis Pharmaceuticals Receives FDA Approval for Its Epinephrine Pre-Filled Syringe
SAN DIEGO , June 15, 2017 (GLOBE NEWSWIRE) --   Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (“PFS”) for the emergency
Adamis Pharmaceuticals Receives FDA Approval for Its Epinephrine Pre-Filled Syringe
SAN DIEGO , June 15, 2017 (GLOBE NEWSWIRE) --   Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (“PFS”) for the emergency
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO , April 26, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the closing of its previously
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO , April 26, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the closing of its previously
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , April 21, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the pricing of its previously
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , April 21, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the pricing of its previously
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 20, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today that it intends to offer to sell
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 20, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today that it intends to offer to sell
Toggle Summary Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)